Mutations in GFPT1 underlie a congenital myasthenic syndrome (CMS) characterized by a limb-girdle pattern of muscle weakness. Glutamine-fructose-6-phosphate transaminase 1 (GFPT1) is a key rate-limiting enzyme in the hexosamine biosynthetic pathway providing building blocks for the glycosylation of proteins and lipids. It is expressed ubiquitously and it is not readily apparent why mutations in this gene should cause a syndrome with symptoms restricted to muscle and, in particular, to the neuromuscular junction. Data from a muscle biopsy obtained from a patient with GFPT1 mutations indicated that there were reduced endplate acetylcholine receptors. We, therefore, further investigated the relationship between identified mutations in GFPT1 and expression of the muscle acetylcholine receptor. Cultured myotubes derived from two patients with GFPT1 mutations showed a significant reduction in cell-surface AChR expression (Pt1 P < 0.0001; Pt2 P 5 0.0097). Inhibition of GFPT1 enzymatic activity or siRNA silencing of GFPT1 expression both resulted in reduced AChR cell-surface expression. Western blot and gene-silencing experiments indicate this is due to reduced steady-state levels of AChR a, d, 1, but not b subunits rather than altered transcription of AChR-subunit RNA. Uridine diphospho-N-acetylglucosamine, a product of the hexosamine synthetic pathway, acts as a substrate at an early stage in the N-linked glycosylation pathway. Similarity between CMS due to GFPT1 mutations and CMS due to DPAGT1 mutations would suggest that reduced endplate AChR due to defective N-linked glycosylation is a primary disease mechanism in this disorder.
INTRODUCTION
Congenital myasthenic syndromes (CMS) comprise a group of genetically and clinically heterogeneous inherited disorders affecting the transmission of signal at the neuromuscular junction. Mutations in a series of genes encoding post-, pre-or synaptic proteins at the NMJ have been associated with CMS (1,2), but surprisingly the two most recent genes in which mutations have been shown to underlie CMS encode ubiquitously expressed proteins in the hexosamine biosynthetic pathway (3) or the N-linked glycosylation pathway (4) . A number of CMS mutations have been identified in the GFPT1 gene (locus 2p13.3) (MIM 610542), which encodes glutamine-fructose-6-phosphate transaminase 1 (GFPT1) (EC ¼ 2.6.1.16) (3, 5) (Fig. 1) , and most recently CMS-causing mutations have been identified in DPAGT1 (4), which encodes dolichyl-phosphate (UDP-Nacetylglucosamine) N-acetylglucosaminephosphotransferase 1.
GFPT1 is a rate-limiting enzyme in the hexosamine biosynthetic pathway providing building blocks for the glycosylation of proteins and lipids. It catalyses the conversion of fructose-6-phosphate and glutamine into glucosamine-6-phosphate and glutamate. Subsequent steps yield the major products of the pathway: uridine diphospho-N-acetylglucosamine (UDP-GlcNAc), UDP-N-acetylgalactosamine and cytidine monophospho sialic acid (6) (Fig. 2) .
Although the GFPT1 gene is expressed in many tissues, its mRNA expression profiles reveal two tissue-specific splice variants, one of which, designated as GFPT1-L, is predominantly expressed in the skeletal muscle and the heart. This subtype contains a 54-bp insertion within the GFPT1-coding sequence, which corresponds to an 18-amino acid insertion at the position 229 in human GFPT1 (7, 8) (Fig. 1) . Mutations in GFPT1 are not restricted to the muscle isoform, but are found along the length of the coding sequence and so would be expected to lead to a multisystem disorder with global impairment in function.
Why mutations in GFPT1 should cause a syndrome associated with impaired neuromuscular transmission with little evidence of impaired function elsewhere is not clear. Here, we investigate disease mechanisms that could lead to the impaired neuromuscular junction transmission that results from mutations in GFPT1.
The susceptibility of the neuromuscular junction to defects of glycosylation is not well understood. This specialized synapse contains many proteins and lipids that are densely packed in a specific subsynaptic distribution (9) . Many of these molecules are modified with carbohydrate structures and many have a repertoire of oligosaccharides that is specific to the neuromuscular junction as opposed to the extrasynaptic parts of the muscle (10) . It is likely, therefore, that the carbohydrate chains play more than a passive role, and are intimately involved in governing correct structure and efficient synaptic function at the neuromuscular junction (11) .
RESULTS

Clinical features
Mutations in GFPT1 were identified in two individuals with a long-standing diagnosis of CMS but in whom a genetic diagnosis had previously remained elusive. Individual 1 (Pt1) harbours heterozygous missense mutations c.1154G.A, Figure 1 . Schematic representation of GFPT1 structure and the localization of the mutations identified in GFPT1 patients. The missense mutations are labelled in black and the truncation mutations are labelled in red. The mutations diagnosed in two British patients, studied in this paper, are labelled in bold. GATase_2, glutamine amidotransferase type 2 domain; SIS, sugar isomerase domain. Figure 2 . Hexosamine biosynthetic and N-glycosylation pathways. Glc, glucose; GlcNAc, N-acetylglucosamine, GlcNH 2 -6-P, glucosamine-6-phosphate; Fru, fructose; P, phosphate. c.1301G.A, p.R385H/R434H; and individual 2 (Pt2) missense mutations c.44C.T, c.1486C.T p.T15M/R496W (3, 5) . Both individuals are white European ethnic origin from the UK. Pt1 was reported to fatigue easily as a child, but presented aged 8 years, when he lost the ability to run and would frequently fall following prolonged exercise. By age 10, he intermittently required a wheelchair, and by 12 years was wheelchair dependent. On examination there was marked weakness with fatiguability of shoulders, hip flexion, elbow and wrist extensors. Facial and ocular muscles were spared. Electromyography on anconeus muscle showed marked decrement of compound muscle action potential on repetitive nerve stimulation at 3 Hz stimulation, and single fibre electromyography grossly abnormal jitter and block.
Pt2 presented at age 6 years with fatigue on walking uphill and a tendency to fall. Motor disability was noted at school and weakness gradually progressed through until his early teenage years when the use of a wheelchair was required. On examination aged 21, there was a marked proximal weakness of shoulders and hips, and weakness at the elbow, wrists and of the small muscles of the hand. Ocular and respiratory muscles were spared. Electromyography showed decrement of compound muscle action potentials following repetitive stimulation at 3 Hz indicative of a defect in neuromuscular transmission.
Muscle biopsies obtained from both patients revealed the presence of tubular aggregates in muscle fibres. Electron microscopy of an intercostal muscle biopsy from Pt2 reported a reduction in postsynaptic folds, and the analysis of endplates revealed reduced miniature endplate amplitudes (0.41 mV + 0.11 vs. normal control 0.69 mV + 0.11, mean + SD) and a reduction in /endplate in control samples, n ¼ 8). Additional analysis of miniature endplate potentials showed an increased rise time (2.7 + 0.6 ms, n ¼ 16, vs. ,1.5 ms for controls), and the quantal content reduced to around a third of normal. In both cases, following the diagnosis of a myasthenic syndrome, anticholinesterase medication (pyridostigmine) was introduced and led to a significant improvement in muscle strength. Subsequently, 3,4-diaminopyridine was instituted as an additional treatment and has provided further benefit. The patients, now aged 25 and 39, respectively, remain stable on the medication, although both require a wheelchair for covering .20-30 m.
GFPT1 protein levels in muscle cells derived from individuals with GFPT1 mutations Muscle cell lines were derived from the two GFPT1 CMS patients and immunoblots performed to establish the levels of GFPT1 protein in myoblast and myotube cultures using anti-GFPT1 antibody (Fig. 3) . The experiments reveal a significant reduction in the expression of the mutated proteins compared with the wild-type controls which is more marked in the myotube cultures.
Cell-surface AChR expression in muscle cells harbouring GFPT1 mutations
The analysis of the muscle biopsy from Pt2 and a positive response to anticholinesterase medication in both Pt1 and Pt2 point to reduced endplate AChR as at least one cause of the impaired neuromuscular transmission observed in GFPT1 CMS patients. We, therefore, measured the cell-surface expression of AChR in skeletal muscle cells (myotubes) derived from controls or from the patients using 125 I-a-bungarotoxin binding. Surface expression of the AChR was significantly reduced in Pt1 and Pt2 cell lines to 27.55 + 2.59% (P , 0.0001) and 80.25 + 6.31% (P ¼ 0.0097), respectively (Fig. 4) .
AChR cell-surface expression following the inhibition of GFPT1 enzymatic activity or GFPT1 gene silencing in TE671 DB40 cells
To further investigate a link between GFPT1 and AChR expression in muscle cells, we used either an inhibitor to block GFPT1 activity, or siRNA to knock down GFPT1 protein levels. Modified TE671 muscle cells (TE671 DB40 cells) which express Figure 3 . GFPT1 expression in wild-type and GFPT1-mutated myoblasts and myotubes from GFPT1 patients (Pt1 and Pt2). Protein extracts from wild-type and GFPT1-mutated myoblasts and myotubes were immunoblotted with anti-GFPT1 and anti-a-tubulin antibodies, and appropriate secondary HRP-conjugated antibodies. The intensities of the bands were measured and GFPT1 expression was normalized to the a-tubulin levels. Each bar represents the average GFPT1 protein levels recorded in n ¼ 5 independent experiments in human skeletal myoblasts and myotubes. Data are expressed relative to the levels of GFPT1 expression in cultures of control myoblasts and myotubes, respectively. high levels of AChR were incubated in increasing concentrations of the GFPT1 inhibitor, 6-diazo-5-oxo-L-norleucine (DON), which is a glutamine analogue commonly used in studies on GFPT1. This inhibitor of GFPT1 caused a concentration-dependent reduction in the surface AChR expression (Fig. 5 ). To confirm this finding, we also silenced GFPT1 expression using siRNA in the TE671 DB40 cells. Two siRNAs, one specific for GFPT1 and one using a scrambled version of the sequence were obtained (Invitrogen) and their silencing capacities assessed by western blotting. Protein levels of GFPT1 in GFPT1 siRNA-transfected cells were reduced by 88.97 + 2.86% (P , 0.0001) compared with the scrambled siRNA-transfected cells ( Fig. 6A and B) indicating efficient knock-down of GFPT1 expression. We then investigated the effect of the GFPT1 knock-down on the cell surface expression of AChR in TE671 DB40 cells. The expression of the receptor at the cell surface in GFPT1 knock-down cells was reduced to 58.85 + 4.97% (P , 0.0001) compared with the cells transfected with scrambled siRNA (Fig. 7) .
Protein levels of AChR subunits in TE671 DB40 cells following GFPT1 silencing by siRNA
To further investigate the mechanisms that underlie the reduction in the surface expression of AChR, we analysed the protein levels of individual subunits in control and GFPT1 knock-down TE671 DB40 cells. Following introduction of siRNA targeting GFPT1, protein was extracted and immunoblotted with respective anti-AChR subunit antibodies (specificity of the antibodies was confirmed by transfection and immunoblots of subunits into HEK293 cells, data not shown). Both AChR a isoforms: P3A+ and P3A2 were recognized by the applied antibody. However, we focused only on the P3A2 isoform, since only the P3A2 form of the a subunit is known to be incorporated into functional AChR (12, 13) . The experiments showed a decrease in the expression of AChR a P3A2, d and 1 subunits [to 30.64 + 8.38% (P ¼ 0.0012), 36.94 + 1.39% (P , 0.0001) and 26.29 + 12.33% (P ¼ 0.0039) of control, respectively] in cells transfected with GFPT1 siRNA compared with the scrambled siRNA transfected cells (Fig. 8) . In contrast, the total protein levels of AChR b subunit appeared not to be affected by the reduction in GFPT1 expression. These results demonstrated a decrease in the steady-state levels of the individual AChR subunits, excluding the b subunit.
mRNA levels of AChR subunits in TE671 DB40 cells with reduced GFPT1 expression
The observed gross reduction in the protein levels of individual AChR a, d and 1 was likely to result from reduced stability of the AChR or potentially from a decrease in the amount of AChR subunits mRNA. For example, aberrant O-GlcNAcetylation of the transcription factors resulting from the GFPT1 mutations could alter the efficiency of transcription of mRNA from the AChR-subunit genes. Since the TE671 DB40 cells are transfected for stable expression of the AChR b, d and 1 subunits under the control of viral promoters, we investigated expression of the AChR a-subunit mRNA. The amount of the CHRNA1 mRNA was quantified in the GFPT1 knock-down and control TE671 DB40 cells using reverse transcription qPCR. The results of the investigations pointed towards a modest reduction (by 18.36 + 5.09%) in the CHRNA1 mRNA levels (Fig. 9) .
Electrophysiology of the AChR in GFPT1 siRNA TE671 cells A further potential mechanism for impaired neuromuscular transmission in patients with GFPT1 mutations might be alteration to the functional properties of the AChR. Potentially alteration of the glycosylation of the AChR could affect conformation and thus the conformational changes required for ion channel activations. We, therefore, made recordings from single channels following GFPT1 silencing in TE671 cells, which express the foetal form of the AChR (Table 1) . We found the single channel function of AChR ion channels expressed by TE671 to be unaffected by silencing of 
DISCUSSION
Mutations in the GFPT1 gene have been found in CMS patients with a characteristic pattern of proximal muscle weakness (3), but the molecular mechanisms that underlie impaired neuromuscular transmission have not been determined. Here, we characterize mutations in GFPT1 and demonstrate that reduced expression of GFPT1 has the potential to impair neuromuscular transmission through reduced cell-surface expression of the muscle AChR at motor endplates. GFPT1 is a key enzyme in the pathway that provides building blocks for glycosylation of proteins and lipids (6) . Post-translational modifications are crucial for a number of key molecules at the neuromuscular junction including the muscle AChR (11) . Our data find reduced endplate AChR numbers in a patient muscle biopsy and demonstrate that in cell culture a reduction in GFPT1 results in a lower cell-surface expression of the AChR. Thus, they provide a potential molecular mechanism through which mutations in the ubiquitously expressed gene could cause CMS.
Muscle AChR is a transmembrane glycoprotein composed of four different subunits in a molar ratio a/b/d/1 2:1:1:1. Each subunit is known to be glycosylated, which is considered important both for the correct assembly of the AChR pentamer and for export of the pentamer from the ER through the golgi to the plasma membrane (14, 15) . Despite a series of studies on the attachment of carbohydrate structures to the AChR (15) (16) (17) (18) (19) (20) (21) (22) , the precise functional role of the oligosaccharide chains remains poorly understood, though the investigations consistently emphasize the crucial role of glycosylation in the surface expression of the receptor (17, (20) (21) (22) (23) (24) (25) . Assays of the levels of GFPT1 in cultured myoblasts and myotubes derived from Pt1 and Pt2 showed reduced levels of GFPT1, consistent with results reported in muscle biopsies from other cases (3). We observed a reduction in endplate AChR as measured by a-bungarotoxin binding in the muscle biopsy from Pt2 (this assay was not done on the biopsy from Pt1). Similarly, myotube cultures derived from the biopsies taken from the GFPT1 patients both gave reduced levels of a-bungarotoxin binding on the cell surface, compared with control cultures, though this was more marked for Pt1. These observations suggest that mutations in GFPT1 have a downstream effect that leads to a reduction in the surface expression of the AChR.
To confirm this effect on AChR protein expression, we replicated impaired GFPT1 activity in a human-derived muscle cell line using a chemical inhibitor of GFPT1 or specific siRNA to silence expression from GFPT1. The use of human muscle cells is relevant for these investigations since the glycosylation has been shown to be species and tissue specific, and the carbohydrate structures attached to the Figure 6 . GFPT1 expression in GFPT1 siRNA knock-down and wild-type TE671 DB40 cells. (A) Protein extracts from GFPT1 siRNA knock-down and wildtype TE671 DB40 cells were immunoblotted with anti-GFPT1 and anti-a-tubulin antibodies, and appropriate secondary HRP-conjugated antibodies. (B) The intensities of the bands were measured and GFPT1 expression was normalized to the a-tubulin levels. Each bar represents the average GFPT1 protein levels recorded in n ¼ 3 independent experiments in GFPT1 siRNA knock-down and wild-type TE671 DB40 cells, respectively. All the data are expressed relative to the levels of GFPT1 in the wild-type cells. I-a-BuTx binding recorded in n ¼ 9 independent experiments to GFPT1 knock-down and wild-type TE671 DB40 cells. The data are expressed relative to the surface over-expressed AChR differ depending on the expression system used. It has been reported that Xenopus oocytes do not possess the ability to synthesize complex glycan structures (26) and at the same time trimming of the core oligosaccharide has been shown to be crucial for regulation of the stability of AChR a subunit, and the surface expression of the receptor in BC3H-1 muscle cells (19) , and late steps of subunits assembly in mouse fibroblast L cells (22) . The studies with the inhibitor DON or siRNA accord with the data obtained using the patients' cells, demonstrating reduced surface expression of the AChR resulting either from the inhibition of GFPT1 enzymatic activity or the down-regulation of its expression.
The likely cause of reduced surface expression of the AChR is impaired glycosylation, since the hexosamine synthetic pathway feeds into the pathway for N-linked glycosylation (Fig. 2) and there are clear-cut phenotypic similarities between patients with mutations in DPAGT1 (4) and patients with GFPT1 mutations (3, 5) . DPAGT1 encodes dolichylphosphate (UDP-N-acetylglucosamine) N-acetylglucosaminesr]phosphotransferase 1, which catalyses the first committed step of the core glycan assembly: the addition of GlcNAc-1-P from cytoplasmic UDP-GlcNAc to dolichol-P. Several mechanisms have been suggested as causative of the reduced surface expression of improperly glycosylated AChR. These include the production of unstable complexes, which are rapidly degraded (17, 25) , or the impairments in the trafficking of the receptor from the endoplasmic reticulum to the cell surface (24) . To provide an insight into the mechanism of the reduced surface expression of the receptor in the absence of GFPT1, we extracted proteins from TE671 DB40 cells following GFPT1 silencing and compared the total protein levels of individual AChR subunits in these cells with wild-type cells. These results show a reduction in the protein levels of the AChR a, d and 1 subunits. Thus, the diminished surface expression of the receptor might at least partially be due to abnormal glycosylation resulting in increased proteolytic degradation leading to reduced steady state levels of individual subunits, similar to a previous report for the requirement for AChR glycosylation in muscle cell cultures (27) . Reduced expression of AChR a subunit resulting from its increased degradation (17) and no effects on AChR b subunit levels (23) are consistent with previous studies, although the reduction of AChR d differs from the previous reports (21, 23) . This may be due to differences in methodology where the role of glycosylation was studied by mutating residues to eliminate one glycosylation site at a time (21, 23) , whereas loss of GFPT1 activity may lead to the impaired glycosylation of all three potential N-linked glycosylation sites in AChR d subunit. Impaired glycosylation may also affect the efficiency of transport of the complexes from ER to the cell surface.
It is possible that the inhibition of GFPT1 function also leads to the reduction of the subunit levels through impaired O-GlcNAcetylation of transcription factors (28) crucial for the regulation of the subunits expression. However, the observation that patients with mutations in DPAGT1 have a phenotype very similar to patients with GFPT1 mutations (4), argues for the same underlying pathway being affected. Moreover, the relative quantification of the CHRNA1 mRNA levels in GFPT1 knock-down and wild type TE671 DB40 cells revealed only a modest reduction in the levels of the CHRNA1 transcript. This modest reduction in CHRNA1 transcript would not be sufficient to cause the large decrease in the AChR a subunit protein we observed.
The electrophysiological properties of the AChR expressed at the cell surface following silencing of GFPT1 were unaffected. This would indicate either that only correctly glycosylated AChR are able to reach the cell surface and thus show normal channel properties, or that glycosylation is not crucial for the ion channel function.
We show decreased surface expression of the AChR resulting from impaired GFPT1 function, either through reduced expression or reduced catalytic activity. These experiments provide a potential molecular mechanism to link impaired neuromuscular transmission with mutations in GFPT1. Since many other proteins localized to the neuromuscular junction are also glycosylated, including proteins involved in AChR clustering and in maintenance of the structure at the neuromuscular synapse, the results do not rule out a possibility that other neuromuscular junction molecules are also affected by GFPT1 mutations. However, the addition of neural agrin to myotubes cultured from a GFPT1 patient muscle biopsy induced efficient AChR clustering that was not distinguishable from controls (see Supplementary Material). Our results would suggest that the AChR is at least one key molecule that is affected by mutations in GFPT1. It remains to be determined why the neuromuscular junction is particularly sensitive to a defect in this ubiquitously expressed protein and why it is predominantly the 'limb-girdle' muscles that are affected.
MATERIALS AND METHODS
Patients
Muscle biopsies were taken from two non-related British patients (Pt1 and Pt2), who both harbour mutations in GFPT1, and have a clinical diagnosis of limb-girdle CMS. Control human skeletal muscle cells were obtained from European Collection of Cell Cultures (ECACC, 06090719). Patient consents were obtained with ethical approval OXREC B: 04.OXB.017 and Oxfordshire REC C 09/H0606/74.
Cell culture
Human skeletal myoblasts were cultured in complete human skeletal muscle cell medium (Promocell) supplemented with 10% foetal bovine serum (FBS), 2 mM L-glutamine and antibiotics in a humidified incubator at 338C. Differentiation into myotubes was induced by changing the medium to Dulbecco's Modified Eagle Medium (DMEM) supplemented with 2% FBS and antibiotics, and culturing the cells at 378C. Figure 9 . CHRNA1 mRNA transcript levels in TE671 DB40 cells following siRNA transfection targeting GFPT1. Total RNA was extracted from GFPT1 siRNA transfected and control TE671 DB40 cells, reverse-transcribed to cDNA and the amount of the CHRNA1 transcript estimated by qPCR. The levels of CHRNA1 mRNA were normalized to the amount of GAPDH transcript. Each bar represents the relative levels of CHRNA1 mRNA recorded in GFPT1 knock-down and control TE671 DB40 cell line in n ¼ 3 experiments performed in triplicates. All the data are expressed relative to the amount of CHRNA1 mRNA in wild-type cells. The experiments were also carried out using the rhabdomyosarcoma cell lines-TE671 (29, 30) and TE671 DB40 (31) . The first one was used for the electrophysiology experiments, since it expresses a single population of endogenously expressed muscle AChR composed of a, b, g and d subunits. The latter cell line-TE671 DB40-was applied in the investigations into the role of GFPT1 in the surface and total expression of AChR, since these cells express higher levels of AChR which are more easily detectable with 125 I-a-BuTx-binding assays or by western blots. The cells were cultured at 378C in DMEM supplemented with 10% FBS and antibiotics.
Inhibition of GFPT1 activity GFPT1 enzymatic activity was inhibited with the glutamine analogue-DON (Sigma, http://www.sigmaaldrich.com/cata log/product/sigma/d2141?lang=en&region=GB). The inhibitor was added to the medium to the final concentration of 100, 200, 500 mM or 1 mM and cells were incubated for 48 h prior to analyses.
Knock-down of GFPT1 expression TE671 or TE671 DB40 cells were transfected with siRNA targeting the GFPT1 transcript sequence 5
′ -CAGAGGATATGA TTCTGCTGGTGT-3 ′ , using lipofectamine RNAiMAX (Invitrogen, 13778). As a control, cells were transfected with scramble siRNA, which did not share significant homology with any sequences in the human genome. I-a-BuTx-bound AChR were solubilized from the cell membrane using extraction buffer (10 mM Tris, 100 mM NaCl, 1 mM EDTA, 1% Triton X-100, pH 8) and the radioactivity was counted on g-counter.
Western blotting
Cells were lysed in buffer (10 mM Tris, 100 mM NaCl, 1 mM EDTA, 1% Triton X-100, pH 7.4) and protein concentration was estimated using BCA kit (Thermo Scientific, 23227). Protein was resolved on 4 -12% Bis -Tris polyacrylamide gels in MOPS buffer and transferred on PVDF membranes, which were subsequently immunoblotted with appropriate primary antibodies: rabbit monoclonal anti-GFPT1 (Epitomics, 3651-1), mouse monoclonal anti-a-tubulin (Sigma, T5168), rat monoclonal anti-AChR a (mAb155), rat monoclonal anti-AChR b (mAb124), which were kindly given by Prof. Socrates Tzartos, goat polyclonal anti-AChR d (Santa Cruz, sc-1451) and goat polyclonal anti-AChR 1 (Santa Cruz, sc-1454) and the respective horseradish peroxidase (HRP)-conjugated secondary antibodies. The density of the bands was measured using GelDoc-It2 310 Imager (UVP) and VisionWorks w LS Image Acquisition and Analysis Software (UVP 97-0186-03).
RNA extraction and RT-qPCR
Total RNA was extracted from TE671 DB40 cells transfected with GFPT1 or scramble siRNA using RNeasy Mini Kit (Qiagen, 74104) according the manufacturer's recommendations. Contaminating DNA was digested with the application of TURBO DNA-free TM kit (Invitrogen, AM1907). 2 mg of total purified RNA was reverse-transcribed using RETROscript TM kit with random decaprimers (Invitrogen, AM1710) according to the supplier's protocol. Additionally, the sample not containing any RNA was reverse-transcribed as a negative control. Quantitative PCR was performed with an Applied Biosystems 7500 Real-Time PCR System using TaqMan w Gene Expression Master Mix (Applied Biosystems, 4369016) following the manufacturer's protocol. Each qPCR reaction was performed in triplicates in 96-well plate and the data were recorded using 7500 Software (Applied Biosystems). The mRNA expression levels of the target gene-CHRNA1-were normalized to the levels of GAPDH house keeping gene expression. The pre-designed assays for the amplification of the target (CHRNA1) and reference (GAPDH) mRNA were purchased from Integrated DNA Technologies. The assay for the amplification of the CHRNA1 contained 5
′ -CAGTAAGACAGAGATGCTCAGAG-3 ′ and 5
′ -TCTACTTCATCGTCAACGTCATC-3 ′ as primers and 5
′ -/56 -FAM/ACCAGGCCA/ZEN/GTTAAGAAGGAGAA GAG/3IABkFQ/-3 ′ as a probe. The assay used for the GAPDH amplification contained the following primers: 5 ′ -TGTAGT TGAGGTCAATGAAGGG-3 ′ and 5 ′ -ACATCGCTCAGA CACCATG -3 ′ and 5 ′ -/56 -FAM/AAGGTCGGA/ZEN/GTC AACGGATTTGGTC/3IABkFQ/-3 ′ as a probe. The RQ values were calculated using 7500 Software (Applied Biosystems). The expression in the cells transfected with scramble siRNA was considered as 100%.
Electrophysiology
Single-channel analysis of AChR function was performed in cultured TE671 cells 48 h after transfection with GFPT1 silencing siRNA, results were compared with TE671 cells transfected with scrambled siRNA. EGFP was co-transfected with GFPT1-targeting siRNA to mark cells successfully transfected, and only green cells were patched. Single-channel analysis was performed using methods previously described (32, 33) . Briefly, cells were subjected to cell-attached patch recordings with 100 nM ACh added to pipette solution to stimulate low levels of AChR activity. Channel burst activity was analysed and fit by three simultaneous exponential populations in pClamp 10 software (Molecular Devices).
Statistical analysis
The statistics were calculated with GraphPad w Prism 5 using two-tailed unpaired t-test. A P-value of ,0.05 was a predetermined threshold for statistical significance.
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